Acura (ACUR) Says Pfizer's (PFE) OXECTA Tabs Now Commercially Available
Tweet
Share
E-mailGet Alerts ACUR Hot Sheet
Join SI Premium – FREE
Acura Pharmaceuticals, Inc. (Nasdaq: ACUR), has been informed by Pfizer, Inc. (NYSE: PFE) that OXECTA (oxycodone HCl, USP) Tablets CII is now commercially available. OXECTA, which utilizes Acura's AVERSION Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg dosage strengths.
Acura has exclusively licensed the AVERSION Technology to Pfizer in the United States, Canada and Mexico for use in four opioid-based pain products. Acura receives tiered royalties ranging from 5% to 25% on net sales (gross sales less discounts, if any) of OXECTA commencing on the first anniversary of the first commercial sale of OXECTA. Pfizer has an option to license the use of the AVERSION technology with additional opioids.
Acura has exclusively licensed the AVERSION Technology to Pfizer in the United States, Canada and Mexico for use in four opioid-based pain products. Acura receives tiered royalties ranging from 5% to 25% on net sales (gross sales less discounts, if any) of OXECTA commencing on the first anniversary of the first commercial sale of OXECTA. Pfizer has an option to license the use of the AVERSION technology with additional opioids.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Provident Financial prices $175M subordinated notes at 6.50%
- LiveRamp shrinks board to six directors after resignation
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
